HU-211

HU-211 is a synthetic cannabinoid that has been extensively studied for its potential therapeutic uses. It is a non-psychoactive derivative of Delta-8-THC, and is also known as Dexanabinol.

History

HU-211 was first synthesized in the 1980s by Professor Raphael Mechoulam at the Hebrew University of Jerusalem, hence the prefix "HU". It was initially developed as part of a research program into cannabinoids and their effects on the brain.

Pharmacology

Unlike most cannabinoids, HU-211 does not act on the cannabinoid receptors in the brain. Instead, it is thought to exert its effects through a variety of other mechanisms. These include the inhibition of NMDA receptors, which are involved in learning and memory, and the reduction of inflammation and oxidative stress.

Clinical uses

HU-211 has been investigated for a number of potential clinical uses. These include the treatment of brain injury, stroke, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. It has also been studied for its potential to reduce the symptoms of multiple sclerosis and to treat pain and seizures.

Research

Research into HU-211 has been extensive, with numerous preclinical and clinical studies conducted. However, despite promising results in early trials, further development of HU-211 as a therapeutic drug has been slow. This is due in part to the complex regulatory environment surrounding cannabinoids, as well as the challenges of drug development more generally.

See also

• Cannabinoids
• Medical cannabis
• Neuroprotection